Wednesday, January 09, 2019 SABCS 2018 Spotlight session drawing crowds - Featuring CCTG MA38 poster Congratulations to the researchers who presented abstracts at two important International research meetings at the end of 2018. Abstracts presented at the 60th ASH Annual Meeting and Exposition MCRN-003 / CCTG MYX.1 - A Single Arm Phase II Study of High-Dose Weekly Carfilzomib plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma After 1-3 Prior Therapies ( onducted in collaboration with the Myeloma Canada Research Network) Alliance A041202 / CCTG CLC.2 – A Randomized Phase III Study of Bendamustine plus Rituximab versus Ibrutinib plus Rituximab versus Ibrutinib Alone in Untreated Older Patients ≥ 65 years of age) with Chronic Lymphocytic Leukemia (CLL) Alliance A10603 / CCTG ALC.2 - A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/ Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PK412) (IND # 101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia (AML) CCTG LY.10 - A Phase II Study of Gemcitabine, Dexamethasone, and Cisplatin (GDP) in Patients With Either Hodgkin's Disease or Aggressive Histology Non-Hodgkin's Lymphoma Which is Relapsed or Refractory Abstracts presented at the Annual San Antonio Breast Cancer Symposium Spotlight Session: Developmental Therapeutics - CCTG MA.38 - Randomized Phase II Study Comparing Two Different Schedules of Palbociclib plus Second Line Endocrine Therapy in Women with Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer Poster Session: Treatment: Adjuvant Therapy - SWOG S0307/CCTG MAC.9 - Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer Spotlight Session: Next Steps in HER2 Targeted Therapy: CCTG MA.31 - A Randomized, Open-Label, Phase III Study of Taxane Based Chemotherapy with Lapatinib Trastuzumab as First-Line Therapy for Women with HER2/neu Positive Metastatic Breast Cancer Poster Session: Epidemiology, Risk, and Prevention: CCTG MAP.3 - A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer Oral Session: General Session: ECOG PACCT-1/ MAC.12 - Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning IndividuaLized Options for Treatment: The TAILORx Trial Poster Session: Treatment: Adjuvant endocrine Therapy. Abstract: Influence of competing risks of death on the interpretation of adjuvant endocrine therapy trials for breast cancer Oral Session: General Session: Regional lymph node irradiation in early stage breast cancer: An EBCTCG metaanalysis of 13,000 women in 14 trials Oral Session: General Session: Effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-specific mortality: An EBCTCG meta-analysis of individual patient data from 12 randomised trials including 24,912 women
